SINGAPORE (Oct 13): DBS Group Research has derived a fair value estimate of 43 cents for iX Biopharma in its preliminary assessment of what it deems a high-risk stock, with a view that investors should expect 0-20% potential returns from the stock over the next 12 months.
The specialty pharmaceutical company currently has five drugs under development: WafeRest for jetlag and improved sleep quality; PheoniX for the treatment of male erectile dysfunction; as well as Wafermine, BnoX and Wafernyl for pain management.
All five drugs leverage on an under-the-tongue delivery technology, WaferiX, which enables quicker absorption and increases the bioavailability of the drugs such that a lower dosage is required.
For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
